PB1205 - Clinical and laboratory characteristics of adults with immune thrombocytopenia in a contemporary cohort in Austria

Tuesday, July 12, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Co-Author(s)

CU

Caroline Ungerböck

MD/PhD Candidate
Department of Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria
Vienna, Wien, Austria
Theresa Schramm, MSc

PhD Student
Department of Medicine I, Clinical Division of Haematology and Haemostaseology; Medical University of Vienna, Vienna, Austria
Vienna, Wien, Austria

Presenting Author(s)

DM

Dino Mehic, MD

Resident physician
Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Vienna, Wien, Austria

Co-Author(s)

MF

Michael Fillitz

Senior Physician
Department of Internal Medicine, Hanusch Krankenhaus, Vienna, Austria
Vienna, Wien, Austria
BD

Barbara Dixer

Chief Study Coordinator
Department of Internal Medicine, Hanusch Krankenhaus, Vienna, Austria,
Vienna, Wien, Austria
Cihan Ay, MD

Professor, Head of the Thrombosis and Haemostasis Research Group
Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Vienna, Wien, Austria
Ingrid Pabinger, MD

Co-Head of the Thrombosis and Haemostasis Research Group
Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Vienna, Wien, Austria
Johanna Gebhart, MD, PhD

Ap. Prof. Dr. PhD
Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Vienna, Wien, Austria

Background: Due to the rarity of primary immune thrombocytopenia (ITP), clinical data on adult patients with primary ITP are scarce.

Aims: The Vienna ITP biobank aims to capture longitudinal clinical data to further characterize Austrian ITP patients.

Methods: The Vienna ITP biobank is an ongoing dual centre biobank (Medical University of Vienna; Hanusch Hospital) that prospectively collects data of patients diagnosed with primary ITP (EC 1843/2016). Patients aged > 18 years are included. At each visit blood is taken for laboratory analyses and the individual medical and bleeding history of each patient is recorded. Bleeding severity is assessed using the ITP ISTH bleeding assessment tool (SMOG BS) and Vicenza BS.

Results: Of 137 included patients, 2 withdrew consent, and 6 were uncovered as secondary ITP after recruitment. Thus, the study cohort comprises a total number of 129 patients. Patients’ and ITP related characteristics are shown in Tables 1 & 2. In total, 27 patients had acute, 13 persistent and 88 chronic ITP at study inclusion. The majority of patients were female, and the mean age was 44.8 years. Half of the patients were under ITP treatment at the time of recruitment and 17 (13.2%) were splenectomized. The median (range) bleeding score was 1.50 (0.0-14.0), 49 patients (38.0%) had no bleeding. Anti-platelet antibodies were detected in 40 patients (31.0%), most of them directed against GP IIb/IIIa. 18 patients (19.8%) had positive antiphospholipid antibodies (APLA), of whom 12 had APLA above the relevant cut-off and 2 fulfilled the diagnosis of antiphospholipid syndrome. Seven patients (7.7%) were double positive, 4 patients (4.4%) had triple positivity.

Conclusion(s): Our cohort of ITP patients shows typical characteristics in respect to clinical and laboratory factors such as age distribution, female predominance, or antibody positivity. We detected a high rate of APLA positivity whose persistence and clinical implications needs to be proven.